Amgen reported strong full-year growth and provided optimistic guidance for 2021, highlighting significant advancements in their pipeline with potential new product launches. Management's positive tone and strategic initiatives to enhance growth despite ongoing COVID-19 challenges are likely to bolster investor confidence in the short term.

[1]